Technology | August 11, 2011

Elekta Deepens Integration of its Oncology Information System With Varian TrueBeam

Stock image

August 11, 2011 – The seamless integration of Elekta's Mosaiq oncology information system (OIS) and Varian's TrueBeam radiation therapy system is enabling the introduction of new OIS functionality, such as flattening filter-free definition, delivery and alerts and enhanced communication capabilities. Numerous TrueBeam users have connected with Mosaiq since the interface was introduced in 2010, and increasing numbers of users are expected to make Mosaiq their OIS. The Mosaiq interface to TrueBeam exemplifies the unparalleled integration between Mosaiq and the radiation therapy systems of other providers, such as Siemens and Accuray/TomoTherapy, and particle therapy vendors, such as Hitachi and IBA.

The Mosaiq OIS streamlines medical oncology and radiation oncology workflows from the first encounter, through diagnosis and staging, planning, treatment and long-term follow-up. At the heart of Mosaiq are the image-enabled electronic medical records (EMR), through which healthcare providers communicate information about their patients during the cancer management continuum.

The work-in-progress Mosaiq functionality for TrueBeam users will include:

  • Characterization of stereotactic cones: In Mosaiq, TrueBeam users will be able to specify field size limitations and other parameters of stereotactic cones and transmit to the linac console.
  • Full support of complex SRS treatments, including complicated deliveries. The Mosaiq interface enables dose verification at the TrueBeam console prior to delivery.
  • Multi-frame imaging, such as fluoro imaging.
  • Gating alerts: Mosaiq will flag the linear accelerator's control system that a particular patient has been prescribed gated therapy delivery.

"At our center we adopted the 'best of breed' approach, where we select the major components of the treatment chain to best suit our clinical practice, and we expect the vendors to ensure seamless exchange of information," says Vladimir Feygelman, Ph.D., faculty physicist at Moffitt Cancer Center in Tampa, Fla. "We were very pleased with the ease of integration, based on the open standards, between the TrueBeam linac and Mosaiq oncology information system."

Mosaiq is the first comprehensive OIS to receive complete EMR certification. Complete EMR certification enables U.S. providers to qualify to demonstrate Stage 1 meaningful use under the HITECH Act.

For more information: www.elekta.com

 

Related Content

Global radiotherapy market revenue is set to expand from $7,222.4 million in 2019 to $17,194.4 million by 2030, at an 8.4% CAGR between 2020 and 2030, the key factor driving the market growth is the increasing number of cancer cases, according to the report published by P&S Intelligence.

Image courtesy of Elekta

News | Radiation Therapy | August 06, 2020
August 6, 2020 — Global ...
Siemens AG is continuing to rigorously execute its Vision 2020+ strategy and therefore expressly welcomes Siemens Healthineers AG’s acquisition of a 100 percent stake in Varian Medical Systems, Inc., a U.S. company active in the area of cancer research and therapy.

Getty Images

News | Radiology Business | August 03, 2020
August 3, 2020 — Siemens AG is continuing to rigorously execute its Vision 2020+ strategy and therefore expressly wel
JAMA Oncol. Published online  July 30, 2020. doi:10.1001/jamaoncol.2020.2783

Table 1. JAMA Oncol. Published online  July 30, 2020. doi:10.1001/jamaoncol.2020.2783

News | Coronavirus (COVID-19) | July 31, 2020
July 31, 2020 — An article published in JAMA...
It has been estimated that the overwhelming focus on COVID-19 could cause up to 35,000 excess cancer deaths in the UK during the next 12 months, and  Zegami, the Oxford University data visualization spin-out which has worked on several projects focused on the detection, diagnosis, or management of cancer, is calling for greater use of technology to speed up the process of diagnosis and treatment.

Getty Images

News | Radiation Oncology | July 29, 2020
July 29, 2020 — It has been estimated that the overwhelming focus on...
In I-131 cancer therapy, decay events damage sensitive DNA within a tumor cell nucleus, causing catastrophic single and double strand breaks. Clinical use of antibody-delivered Auger emitters could open a window for the targeted destruction of extracellular COVID-19 virions, decreasing the viral load during active infection and potentially easing the disease burden for a patient. View all figures from this study.  http://jnm.snmjournals.org/content/early/2020/07/16/jnumed.120.249748.full.pdf+html

In I-131 cancer therapy, decay events damage sensitive DNA within a tumor cell nucleus, causing catastrophic single and double strand breaks. Clinical use of antibody-delivered Auger emitters could open a window for the targeted destruction of extracellular COVID-19 virions, decreasing the viral load during active infection and potentially easing the disease burden for a patient. View all figures from this study.

 

News | Coronavirus (COVID-19) | July 22, 2020 | Dave Fornell, Editor
July 22, 2020 — One of the first studies has been published that looks at the use of...
World's largest radiation oncology meeting will offer full conference on interactive platform October 25-28, 2020
News | ASTRO | July 09, 2020
July 9, 2020 — Registration opens today for the American Society for Radiation Oncology's (...
Radiotherapy has been used to treat cancers for more than a century and continues to be utilized in cancer treatment plans today. Since the introduction of radiotherapy, clinicians have been working tirelessly to further refine treatments to better target cancer.
Feature | Radiation Therapy | July 06, 2020 | By Yves Archambault
Everything has room for improvement, right? Right. When it comes to cancer care, it is no different.
Proton therapy has evolved, and future predictions include smaller systems, more sophisticated proton dosimetry and devices that manipulate the proton beam
Feature | Proton Therapy | July 06, 2020 | By Minesh Mehta, M.D.
The field of proton...